New Trade Margin Rule to Cut Non‑Scheduled Cancer Medicine Costs
The government has introduced a Trade Margin Regulation for 137 non‑scheduled anti‑cancer drugs, limiting the trade margin to 30 % of the Maximum Retail Price. Expected reductions of up to 70 % in retail prices will start from 9 November 2026. The decision follows the success of a 2019 pilot that restricted margins on 42 oncology medicines and led to price drops of up to 90 % across 526 brands. An expert panel of leading cancer specialists, clinicians and officials reviewed the drug list and will periodically revise it. Under Section 19 of the Drug (Price Control) Order, manufacturers must submit the new MRP within a week of the Gazette release and publish the figures on their websites, ensuring retailers and hospitals sell at the lower rates. The initiative aims to lessen the economic burden on patients undergoing cancer therapy.